Targeting 5α-reductase with 99mTc labeled dutasteride derivatives for prostate imaging

Gul-e-Raana; Syed Qaiser Shah

doi:10.1515/ract-2019-3156

Article

Targeting 5α-reductase with ^99mTc labeled dutasteride derivatives for prostate imaging

Gul-e-Raana and Syed Qaiser Shah

Published/Copyright: September 13, 2019

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information Explore this Subject

From the journal Radiochimica Acta Volume 108 Issue 4

Abstract

To assess the suitability of ^99mTc labeled 5α-reductase (5α-Rds) inhibitors for non-invasive targeting of prostate cancer (PCa) using Male Sprague Dawely Rat (MSDR) model. In this work, dutasteride (Cpd-1) a 5α-Rds inhibitor was derivatized to its dithiocarbamate analogue (Cpd-2) for subsequent synthesis of ^99mTc(CO)₃-dutasteride dithiocarbamate (Cpd-3) using tricarbonyl technique. To determine the structure of Cpd-3, for the first time a reference Re(CO)₃-dutasteride dithiocarbamate (Cpd-4) was synthesized and characterized with NMR, ESIMS, HPLC and elemental analysis. HPLC was used to establish the identity of Cpd-3 using Cpd-4 as a reference standard. The suitability of Cpd-3 as a new 5α-Rds targeting agent was investigated, both in vitro and vivo. The Cpd-3 has shown ≥98 % in vitro stability at room temperature and was remained ≥90 % stable up to 6 h. In serum Cpd-3 has revealed an analogous behavior with a small decrease in stability after 16 h. High uptake (26.25 ± 1.10 %, after 4 h of i.v.) of Cpd-3 was observed in the prostate (target tissue) of MSDR model with reasonably good target to non-target ratio. Blocking the target site with excess Cpd-2 considerably decreased the uptake of Cpd-3 to 4.10 ± 0.75 % in PCa. High in vitro stability in saline and serum and in vivo uptake in prostate of MSDR model plausibly attracts the opportunity of using Cpd-3 as a novel radiopharmaceutical for non invasive targeting of prostate.

Keywords: Dutasteride; 5α-reductase inhibitor; tricarbonyl core; prostate cancer

References

1. Catalona, W. J.: Prostate cancer screening. Med. Clin. North. Am. 102, 199 (2018).10.1016/j.mcna.2017.11.001Search in Google Scholar PubMed PubMed Central

2. Dunn, M. W.: Prostate cancer screening. Semin. Oncol. Nurs. 33, 156 (2017).10.1016/j.soncn.2017.02.003Search in Google Scholar PubMed

3. Ugge, H., Udumyan, R., Carlsson, J., Andren, O., Montgomery, S., Davidsson, S., Fall, K.: Acne in late adolescence and risk of prostate cancer. Int. J. Cancer 142, 1580 (2018).10.1002/ijc.31192Search in Google Scholar PubMed PubMed Central

4. Cheng, M. A., Chou, F. J., Wang, K. L., Yang, R., Ding, J., Zhang, Q. X., Li, G. H., Yeh, S. Y., Chang, C., Xu, D. F.: Androgen receptor (AR) degradation enhancer ASC-J9 (R) in an FDA-approved formulated solution suppresses castration resistant prostate cancer cell growth. Cancer Lett. 417, 182 (2018).10.1016/j.canlet.2017.11.038Search in Google Scholar PubMed

5. O’Connor, M. K., Kemp, B. J.: Single-photon emission computed tomography/computed tomography: basic instrumentation and innovations. Semin. Nucl. Med. 36, 258 (2006).10.1053/j.semnuclmed.2006.05.005Search in Google Scholar PubMed

6. Schillaci, O.: Hybrid SPECT/CT: a new era for SPECT imaging? Eur. J. Nucl. Med. Mol. Imaging 32, 521 (2005).10.1007/s00259-005-1760-9Search in Google Scholar PubMed

7. Bolouri, C., Merwald, M., Huellner, M. W., Veit-Haibach, P., Kuttenberger, J., Pérez-Lago, M., Seifert, B., Strobel, K.: Performance of orthopantomography, planar scintigraphy, CT alone and SPECT/CT in patients with suspected osteomyelitis of the jaw. Eur. J. Nucl. Med. Mol. Imaging 40, 411 (2013).10.1007/s00259-012-2285-7Search in Google Scholar PubMed

8. Bar-Shalom, R., Yefremov, N., Guralnik, L., Keidar, Z., Engel, A., Nitecki, S., Israel, O.: SPECT/CT using ⁶⁷Ga and ¹¹¹In-labeled leukocyte scintigraphy for diagnosis of infection. J. Nucl. Med. 47, 587 (2006).Search in Google Scholar

9. Schillaci, O., Simonetti, G.: Fusion imaging in nuclear medicine applications of dual-modality systems in oncology. Cancer Biother. Radiopharm. 19, 1 (2004).10.1089/108497804773391621Search in Google Scholar PubMed

10. Anconina, R., Hod, N., Levin, D., Kazap, D. E., Lantsberg, S.: Incidental detection of metastatic malignant melanoma on 68Ga-prostate-specific membrane antigen PET/CT imaging: correlative imaging with FDG PET/CT and review of the literature. Clin. Nucl. Med. 43, 204 (2018).10.1097/RLU.0000000000001959Search in Google Scholar PubMed

11. Valicenti, R. K., Pugh, S. L., Trabulsi, E. J., Sartor, O., Ko, E. C., Girvigian, M. R., Rosenthal, S. A., Shaves, M. E., Hoffman-Censits, J. H., Schallenkamp, J., Sandler, H. M.: First report of NRG oncology/radiation therapy oncology group 0622: a phase 2 trial of Samarium-153 followed by salvage prostatic fossa irradiation in high-risk clinically nonmetastatic prostate cancer after radical prostatectomy. Int. J. Radiat. Oncol. Biol. Phys. 100, 695 (2018).10.1016/j.ijrobp.2017.11.024Search in Google Scholar PubMed PubMed Central

12. Zaghian, M., Lim, G. J., Khabazian, A.: A chance-constrained programming framework to handle uncertainties in radiation therapy treatment planning. Eur. J. Oper. Res. 266, 736 (2018).10.1016/j.ejor.2017.10.018Search in Google Scholar

13. Ehrbar, S., Schmid, S., Johl, A., Klock, S., Guckenberger, M., Riesterer, O., Tanadini-Lang, S.: Comparison of multi-leaf collimator tracking and treatment-couch tracking during stereotactic body radiation therapy of prostate cancer. Radiother. Oncol. 125, 445 (2017).10.1016/j.radonc.2017.08.035Search in Google Scholar PubMed

14. Kim, S. Y., Lee, H. K., Ju, M. S., Joo, S. H., Cho, J. H.: Treatment planning volume according to change in bladder volume in therapy of proton beam in magnetic field. J. Magn. 22, 665 (2017).10.4283/JMAG.2017.22.4.665Search in Google Scholar

15. Iravani, A., Hofman, M. S., Mulcahy, T., Williams, S., Murphy, D., Parameswaran, B. K., Hicks, R. J.: Ga-68 PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer. Cancer Imaging 17, 31 (2017).10.1186/s40644-017-0133-5Search in Google Scholar PubMed PubMed Central

16. Avila-Rodriguez, M. A., Rios, C., Carrasco-Hernandez, J., Manrique-Arias, J. C., Martinez-Hernandez, R., Garcia-Perez, F. O., Jalilian, A. R., Martinez-Rodriguez, E., Romero-Pina, M. E., Diaz-Ruiz, A.: Biodistribution and radiation dosimetry of [Cu-64]copper dichloride: first-in-human study in healthy volunteers. EJNMMI Res. 7, 98 (2017).10.1186/s13550-017-0346-4Search in Google Scholar PubMed PubMed Central

17. Kelly, J. M., Amor-Coarasa, A., Nikolopoulou, A., Kim, D., Williams, C., Vallabhajosula, S., Babich, J. W.: Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: stability and complexation kinetics of Ga-68(3+), In-111(3+), Lu-177(3+.), and (225)AC(3+). Nucl. Med. Biol. 55, 38 (2017).10.1016/j.nucmedbio.2017.10.001Search in Google Scholar PubMed

18. Fennessy, N., Lee, J., Shin, J., Ho, B., Ali, S. A., Paschkewitz, R., Emmett, L.: Frusemide aids diagnostic interpretation of Ga-68-PSMA positron emission tomography/CT in men with prostate cancer. J. Med. Imaging Radiat. Oncol. 61, 739 (2018).10.1111/1754-9485.12625Search in Google Scholar PubMed

19. Mease, R. C., Dusich, C. L., Foss, C. A.: N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-[¹⁸F]fluorobenzyl-Lcysteine, [¹⁸F]DCFBC: a new imaging probe for prostate cancer. Clin. Cancer Res. 14, 3036 (2008).10.1158/1078-0432.CCR-07-1517Search in Google Scholar PubMed PubMed Central

20. Russell, D. W., Wilson, J. D.: Steroid 5α-reductase: two genes/two enzymes. Annu. Rev. Biochem. 63, 25 (1994).10.1146/annurev.bi.63.070194.000325Search in Google Scholar PubMed

21. Thiboutot, D., Harris, G., Iles. V., Cimis, G., Gilliland, K., Hagari, S.: Activity of the type I 5α-reductase exhibits regional differences in isolated sebaceous glands and whole skin. J. Invest. Dermatol. 105, 209 (1995).10.1111/1523-1747.ep12317162Search in Google Scholar PubMed

22. Courchay, G., Boyera, N., Bernard, B. A., Mahe, Y.: Messenger RNA expression of steroidogenesis enzyme subtypes in the human pilosebaceous unit. Skin Pharmacol. 9, 169 (1996).10.1159/000211412Search in Google Scholar

23. Imperato-McGinley, J., Guerrero, L., Gautier, T., Peterson, R. E.: Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 186, 1213 (1974).10.1097/00006254-197505000-00017Search in Google Scholar

24. Walsh, P. C., Madden, J. D., Harrod, M. J., Goldstein, J. L., MacDonald, P. C., Wilson, J. D.: Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N. Engl. J. Med. 291, 944 (1974).10.1056/NEJM197410312911806Search in Google Scholar

25. Hudson, P. B., Boake, R., Trachtenberg, J., Romas, N. A., Rosenblatt, S., Narayan, P., Geller, J., Lieber, M. M., Elhilali, M., Norman, R., Patterson, L., Perreault, J. P., Malek, G. H., Brusketwitz, R. C., Roy, J. B., Ko, A., Jacobsen, C. A., Stoner, E.: Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group. Urology 53, 690 (1999).10.1016/S0090-4295(98)00666-9Search in Google Scholar

26. McConnell, J. D., Bruskewitz, R., Walsh, P., Andriole, G., Lieber, M., Holtgrewe, H. L., Albertsen, P., Roehrborn, C. G., Nickel, J. C., Wang, D. Z., Taylor, A. M., Waldstreicher, J.: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N. Engl. J. Med. 338, 557 (1998).10.1056/NEJM199802263380901Search in Google Scholar PubMed

27. Jan, G., Passi, N. D., Dhawan, D. K., Chadha, V. D.: Cancer targeting potential of ^99mTc-finasteride in experimental model of prostate carcinogenesis. Cancer Biother. Radiopharm. 32, 39 (2017).10.1089/cbr.2016.2032Search in Google Scholar PubMed

28. Shah, S. Q., Raana, G., Uddin, G.: Imaging prostate cancer (PCa) with [^99mTc(CO)₃]finasteride. J. Label. Compd. Radiopharm. 61, 550 (2018).10.1002/jlcr.3621Search in Google Scholar PubMed

29. Nickel, J. C.: Comparison of clinical trials with finasteride and dutasteride. Rev. Urol. 6(Suppl 9), S31 (2004).Search in Google Scholar

30. Chung, H. C., Lee, S., Lee, W. S.: Long-term efficacy and safety of the dual 5-alpha reductase blocker dutasteride on male androgenetic alopecia patients. J. Dermatol. 44, 1408 (2017).10.1111/1346-8138.13710Search in Google Scholar PubMed

31. Moreira, D. M., Andriole, G. L., Nickel, J. C., Roehrborn, C. G., Castro-Santamaria, R., Freedland, S. J.: Dutasteride is associated with reduced risk of transrectal prostate biopsy-associated urinary tract infection and related hospitalizations. World. J. Urol. 35, 1525 (2017).10.1007/s00345-017-2036-2Search in Google Scholar PubMed

32. Shah, S. Q., Khan, M. R.: ^99mTcN–gatifloxacin dithiocarbamate complex: a novel multi-drug-resistance Streptococcus pneumoniae (MRSP) infection radiotracer. J. Radioanal. Nucl. Chem. 289, 903 (2011).10.1007/s10967-011-1180-1Search in Google Scholar

Received: 2019-04-17

Accepted: 2019-08-12

Published Online: 2019-09-13

Published in Print: 2020-03-26

You are currently not able to access this content.

Articles in the same Issue

https://doi.org/10.1515/ract-2019-3156

Keywords for this article

Dutasteride; 5α-reductase inhibitor; tricarbonyl core; prostate cancer